Managed Entry Agreements (MEAs) play a pivotal role in addressing the challenges arising from escalating prices of innovative medical technologies, especially in areas like oncology, immunology, and rare diseases. Among MEAs, Performance-Based MEAs (PB MEAs) and Outcome-Based MEAs (OB MEAs) stand out as innovative strategies. This study examines the adoption of PB MEAs in the Czech Republic post a 2022 legislative change. Interviews with key stakeholders, including the Ministry of Health, pharmaceutical companies, insurers, and patient groups, were conducted to explore perceptions and challenges. Stakeholders expressed concerns about legislation completeness, data quality, transparency, and methodology. Interestingly, pharmaceutical companies were less concerned about transparency and methodology, likely due to their multinational experience. Despite legislative progress, challenges persist, especially in data infrastructure, risk-sharing perceptions, and stakeholder readiness. Addressing these issues requires collaboration between pharmaceutical companies and payers. Patient involvement, though mandated, remains limited, potentially due to a lack of awareness. This study emphasizes the need for a comprehensive transformation beyond legislation for a successful PB MEA implementation. Trust, technical infrastructure, and data availability are crucial, necessitating a holistic approach. It contributes to the global discourse on PB MEAs, stressing the adjustment of financial frameworks, embracing value-based healthcare principles, and ensuring high-quality health data metrics. A more holistic, value-based MEA approach could reshape pharmaceutical reimbursement in the future.

Departement of Biomedical Technology Faculty of Biomedical Engineering Czech Technical University Prague 272 01 Kladno Czech Republic

Zobrazit více v PubMed

Ferrario A., Arāja D., Bochenek T., Čatić T., Dankó D., Dimitrova M., Fürst J., Greičiūtė-Kuprijanov I., Hoxha I., Jakupi A., et al. The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications. PharmacoEconomics. 2017;35:1271–1285. doi: 10.1007/s40273-017-0559-4. PubMed DOI PMC

Klemp M., Frønsdal K.B., Facey K. What principles should govern the use of managed entry agreements? Int. J. Technol. Assess. Health Care. 2011;27:77–83. doi: 10.1017/S0266462310001297. PubMed DOI

Gamba S., Pertile P., Vogler S. The impact of managed entry agreements on pharmaceutical prices. Health Econ. 2020;29:47–62. doi: 10.1002/hec.4112. PubMed DOI

Ciulla M., Marinelli L., Di Biase G., Cacciatore I., Santoleri F., Costantini A., Dimmito M.P., Di Stefano A. Healthcare Systems across Europe and the US: The Managed Entry Agreements Experience. Healthcare. 2023;11:447. doi: 10.3390/healthcare11030447. PubMed DOI PMC

Pauwels K., Huys I., Vogler S., Casteels M., Simoens S. Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future. Front. Pharmacol. 2017;8:171. doi: 10.3389/fphar.2017.00171. PubMed DOI PMC

Ferrario A., Kanavos P. Dealing with uncertainty and high prices of new medicines: A comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden. Soc. Sci. Med. 2015;124:39–47. doi: 10.1016/j.socscimed.2014.11.003. PubMed DOI

Stafinski T., McCabe C.J., Menon D. Funding the Unfundable. PharmacoEconomics. 2010;28:113–142. doi: 10.2165/11530820-000000000-00000. PubMed DOI

Carlson J.J., Chen S., Garrison L.P. Performance-Based Risk-Sharing Arrangements: An Updated International Review. PharmacoEconomics. 2017;35:1063–1072. doi: 10.1007/s40273-017-0535-z. PubMed DOI

Wenzl M., Chapman S. Performance-Based Managed Entry Agreements for New Medicines in OECD Countries and EU Member States: How They Work and Possible Improvements Going Forward. OECD Health Working Papers. 2019. [(accessed on 3 April 2022)]. Available online: https://www.oecd-ilibrary.org/social-issues-migration-health/performance-based-managed-entry-agreements-for-new-medicines-in-oecd-countries-and-eu-member-states_6e5e4c0f-en.

Dabbous M., Chachoua L., Caban A., Toumi M. Managed Entry Agreements: Policy Analysis from the European Perspective. Value Health. 2020;23:425–433. doi: 10.1016/j.jval.2019.12.008. PubMed DOI

Vlasakova M., Muzik J., Holubová A., Fiala D., Arsand E., Urbanová J., Žďárská D.J., Brabec M., Brož J. A Telemedicine System Intervention for Patients with Type 1 Diabetes: Pilot Feasibility Crossover Intervention Study. JMIR Form. Res. 2023;7:e35064. doi: 10.2196/35064. PubMed DOI PMC

Hospodková P., Gilíková K., Barták M., Marušáková E., Tichopád A. Opportunities and Threats of the Legally Facilitated Performance-Based Managed Entry Agreements in Slovakia: The Early-Adoption Perspective. Healthcare. 2023;11:1179. doi: 10.3390/healthcare11081179. PubMed DOI PMC

Gerkens S., Neyt M., San Miguel L., Vinck I., Thiry N., Cleemput I. How to Improve the Belgian Process for Managed Entry Agreements? An Analysis of the Belgian and International Experience 2017. [(accessed on 16 December 2022)]. Available online: www.kce.fgov.be.

Kanavos P., Ferrario A., Tafuri G., Siviero P. Managing Risk and Uncertainty in Health Technology Introduction: The Role of Managed Entry Agreements. Glob. Policy. 2017;8:84–92. doi: 10.1111/1758-5899.12386. DOI

Rotar A.M., Preda A., Löblová O., Benkovic V., Zawodnik S., Gulacsi L., Gulacsi L., Niewada M., Boncz I., Petrova G., et al. Rationalizing the introduction and use of pharmaceutical products: The role of managed entry agreements in Central and Eastern European countries. Health Policy. 2018;122:230–236. doi: 10.1016/j.healthpol.2018.01.006. PubMed DOI

Reed M.S., Graves A., Dandy N., Posthumus H., Hubacek K., Morris J., Prell C., Quinn C.H., Stringer L.C. Who’s in and why? A typology of stakeholder analysis methods for natural resource management. J. Environ. Manag. 2009;90:1933–1949. doi: 10.1016/j.jenvman.2009.01.001. PubMed DOI

Palinkas L.A., Horwitz S.M., Green C.A., Wisdom J.P., Duan N., Hoagwood K. Purposeful Sampling for Qualitative Data Collection and Analysis in Mixed Method Implementation Research. Adm. Policy Ment. Health Ment. Health Serv. Res. 2015;42:533–544. doi: 10.1007/s10488-013-0528-y. PubMed DOI PMC

Lübbeke A., Carr A.J., Hoffmeyer P. Registry stakeholders. EFORT Open Rev. 2019;4:330–336. doi: 10.1302/2058-5241.4.180077. PubMed DOI PMC

Hsieh H.F., Shannon S.E. Three approaches to qualitative content analysis. Qual. Health Res. 2005;15:1277–1288. doi: 10.1177/1049732305276687. PubMed DOI

Henderson R. Doing Qualitative Research: A Practical Handbook. Volume 4. SAGE Publications Inc.; Thousand Oaks, CA, USA: 2013.

de Pouvourville G., Cunningham D., Fricke F.U., Lindgren P., Mantovani L., Murphy L.A., Solà-Morales O., Mestre-Ferrandiz J., Akehurst R. Across-Country Variations of Real-World Data and Evidence for Drugs: A 5-European-Country Study. Value Health. 2023;26:3–10. doi: 10.1016/j.jval.2023.01.009. PubMed DOI

Xoxi E., Rumi F., Kanavos P., Dauben H.P., Gutierrez-Ibarluzea I., Wong O., Rasi G., Rasi G. A Proposal for Value-Based Managed Entry Agreements in an Environment of Technological Change and Economic Challenge for Publicly Funded Healthcare Systems. Front. Med. Technol. 2022;4:888404. doi: 10.3389/fmedt.2022.888404. PubMed DOI PMC

Implementing performance-based risk-sharing agreements in non-small cell lung cancer immunotherapy: a real-world data case study